Targeted Therapies Compared to Dacarbazine for Treatment of BRAF<sup>V600E</sup> Metastatic Melanoma: A Cost-Effectiveness Analysis

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">Total cost</td><td align="center">Total effectiveness</td><td align="center">Incremental cost</td><td align="center">Incremental effectiveness</td><td align="center">ICER</td></tr><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr><td align="left">Dacarbazine</td><td align="center">$15,221</td><td align="center">0.1820 QALYs</td><td align="center"> </td><td align="center"> </td><td align="center"> </td></tr><tr><td align="left">Vemurafenib</td><td align="center">$49,938</td><td align="center">0.2905 QALYs</td><td align="center">$34,717</td><td align="center">0.1085 QALYs</td><td align="center">$319,972</td></tr><tr class="table-tr"><td colspan="6"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>QALYs: quality-adjusted life years; ICER: incremental cost-effectiveness ratio.<br/>Note: comparison is to the chemotherapy drug option. <br/></td></tr></table>

Base case cost-effectiveness of vemurafenib relative to dacarbazine.

Journal of Skin Cancer

tab3

Table 3

Table 3: Targeted Therapies Compared to Dacarbazine for Treatment of BRAF<sup>V600E</sup> Metastatic Melanoma: A Cost-Effectiveness Analysis 

Journal of Skin Cancer

Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis

Table 3

Targeted Therapies Compared to Dacarbazine for Treatment of BRAF^V600E Metastatic Melanoma: A Cost-Effectiveness Analysis